SKYCLARYS, the First and Only FDA-Approved Prescription Treatment for Friedreich Ataxia in Adults and Adolescents Aged 16 Years or Older

Date/Time: Monday, September 16 | 4:15 PM - 5:45 PM
Track: Satellite Symposia
Room: Lake Mizell A

SPONSORED BY BIOGEN

Image

Description:
This presentation will include an introduction into the clinical background of Friedreich Ataxia (FA), a summary of the clinical efficacy and safety data from the clinical trials that studied SKYCLARYS in the treatment of FA, and the clinical management of treatment with SKYCLARYS. 

Speaker:
Omer A. Abdul Hamid, MD
Attending Physician, Neuromuscular & Electrodiagnostic Medicine/ General Child Neurology, Nemours Children’s Hospital, Division of Neurology